Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Sintilimab + Bevacizumab in Advanced Liver Cancer
NCT06408623Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in hepatocellular carcinoma (HCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 24 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06408623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408623.